<p style="text-align: justify;"><b>Dietary Exposure</b></p>

<p style="text-align: justify;">The human consumption of the modified tomato line 1345-5 will be as both fresh and processed tomato products. Fresh market tomatoes are eaten whole and sliced or diced in a variety of foods. Processed tomatoes are consumed in the form of soups, preserves, ketchup, paste and prepared sauces. The genetic modification of these novel hybrids will not result in any change in the consumption pattern for fresh or processed tomato products. Line 1345-4 is expected to replace other tomato cultivars currently in use due to improved quality and handling characteristics. Hence, it will provide an alternate or additional choice to consumers and food manufacturers.</p>

<p style="text-align: justify;"><b>Nutritional Data</b></p>

<p style="text-align: justify;">The analysis of nutrients from the novel 1345-4 line and the non-transgenic 91103-114 parental line did not reveal any significant differences in the levels of macro- and micronutrients. The presence of NPTII protein was judged to be insignificant with respect to any human health risk due to exposure. The consumption of this product will, therefore, have no significant impact on the nutritional quality of the food supply in Canada and the United States. Tomatoes produce naturally occurring glycoalkaloids, alpha-tomatine being the most common. The level of alpha-tomatine decreases as the fruit matures, so that the amounts in vine-ripened red tomatoes are negligible. The concentration of alpha-tomatine in immature tomatoes from transgenic line 1345-4 was 1.13-1.37 mg/100g fresh weight tissue, as compared with 3.37-3.59 mg/100g fresh weight tissue for the unmodified 91103- 114 parental line. However, these levels evened out once the fruit ripened into mature red tomatoes. In vine-ripened red tomatoes, the amount of alpha-tomatine in transgenic tomatoes was 0.11/100g fresh weight tissue compared to 0.07 mg/100g fresh weight tissue in the non-transgenic parental line. Other than reduced ACC synthase activity, the disease, pest and other agronomic characteristics of the transgenic 1345-4 line were comparable to the unmodified parental line.</p>

<p style="text-align: justify;"><b>Toxicity and Allergenicity</b></p>

<p style="text-align: justify;">The reduced synthesis of native ACC synthase was judged not to have any potential for additional human toxicity or allergenicity. The truncated ACC synthase gene was not expressed in line 1345-4 and should not have any toxic or allergenic properties. The NPTII protein is widespread in nature and no toxic or allergenic effects have ever been reported.</p>
